Showing results (151-160 of 160) with videos related to

Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 160 results.
European Journal of Nuclear Medicine and Molecular Imaging|December 21, 2021
89Zr-labeled PSMA ligands for pharmacokinetic PET imaging and dosimetry of PSMA-617 and PSMA-I&T: a preclinical evaluation and first in manBastiaan M Privé, Yvonne H W Derks, Florian Rosar, et al.
The Journal of Urology|February 22, 2021
Robotic Salvage Lymph Node Dissection in Recurrent Prostate Cancer: Lessons Learned from 68 Cases and Implications for Future Clinical ManagementJohannes Linxweiler, Jan Sprenk, Katerina Cascetta, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 26, 2025
Early changes of PSMA PET expression after initiation of androgen receptor signaling inhibitors in CRPC: an international multicenter retrospective studyLena M Unterrainer, Andrea Farolfi, Tristan Grogan, et al.
Journal of Hepatology|May 28, 2013
Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinomaRita Golfieri, Josè Ignacio Bilbao, Livio Carpanese, et al.
Hepatology (Baltimore, Md.)|May 28, 2011
Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluationBruno Sangro, Livio Carpanese, Roberto Cianni, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 9, 2018
Radioembolisation in patients with hepatocellular carcinoma that have previously received liver-directed therapiesBruno Sangro, Carlo Ludovico Maini, Giuseppe Maria Ettorre, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 24, 2019
EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT)Clemens Kratochwil, Wolfgang Peter Fendler, Matthias Eiber, et al.
Prostate Cancer and Prostatic Diseases|July 13, 2021
Impact of DNA damage repair defects on response to PSMA radioligand therapy in metastatic castration-resistant prostate cancerBastiaan M Privé, Peter H J Slootbeek, Babette I Laarhuis, et al.
Cancers|January 8, 2023
PSMA-RLT in Patients with Metastatic Hormone-Sensitive Prostate Cancer: A Retrospective StudyAmina Banda, Bastiaan M Privé, Youssra Allach, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 29, 2023
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)Clemens Kratochwil, Wolfgang P Fendler, Matthias Eiber, et al.
Pageof 16